Healx
Transforming lives for rare disease patients
Traditional drug discovery is slow, expensive and has a 5% success rate. This has led to a culture of filling pipelines with blockbuster drugs, targeted to large patient populations, in order to offset the cost of failures. By using AI and other frontier technologies to redevelop, combine and enhance known compounds, we are building a pipeline of new and effective therapies.
Pioneering the next generation of drug discovery
We bring treatments from prediction to patient. Artificial intelligence enables us to rapidly identify which novel drug-disease relationships have the highest chance of success and effectively scale a drug pipeline that will deliver significant patient impact.
By using technology to de-risk the drug discovery process, we can run multiple programmes in parallel and deliver a higher chance of treatment success.
Latest news and articles
News & Opinion
Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform
News & Opinion
U.S. FDA Grants Fast Track designation for HLX-1502 in Neurofibromatosis Type 1 (NF1) Treatment
News & Opinion
Healx Announces $47 million Series C Financing and FDA Clearance of Phase 2 IND for Neurofibromatosis Type 1 Trial
Careers
We’re a diverse team of talented people working to revolutionise the way rare disease treatments are discovered and developed.
Our team has a broad range of expertise, experience, and perspectives but what unites us is our drive to make a positive difference to rare disease patients and their families.